Richard Hamman
Concepts (612)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Diabetes Mellitus, Type 2 | 78 | 2022 | 1416 | 4.490 |
Why?
| Diabetes Mellitus, Type 1 | 57 | 2022 | 2293 | 3.250 |
Why?
| Attitude | 86 | 2018 | 47516 | 2.210 |
Why?
| Engineering | 85 | 2018 | 47370 | 2.210 |
Why?
| Social Responsibility | 85 | 2018 | 47385 | 2.210 |
Why?
| Students | 85 | 2018 | 47688 | 2.200 |
Why?
| Diabetes Mellitus | 18 | 2021 | 636 | 1.900 |
Why?
| Female | 265 | 2022 | 92196 | 1.490 |
Why?
| Male | 248 | 2022 | 90667 | 1.470 |
Why?
| Humans | 297 | 2022 | 128242 | 1.380 |
Why?
| Adult | 192 | 2022 | 70001 | 1.380 |
Why?
| Adolescent | 156 | 2022 | 60563 | 1.370 |
Why?
| Cardiovascular Diseases | 18 | 2019 | 1211 | 1.290 |
Why?
| Young Adult | 115 | 2022 | 55149 | 1.250 |
Why?
| Longitudinal Studies | 92 | 2018 | 49312 | 1.140 |
Why?
| Colorado | 70 | 2021 | 3230 | 1.110 |
Why?
| Socialization | 85 | 2018 | 47368 | 1.100 |
Why?
| Curriculum | 86 | 2018 | 47915 | 1.090 |
Why?
| Interviews as Topic | 86 | 2018 | 47819 | 1.090 |
Why?
| Cholesterol, HDL | 15 | 2019 | 183 | 1.090 |
Why?
| Surveys and Questionnaires | 93 | 2018 | 50539 | 1.090 |
Why?
| Risk Factors | 79 | 2021 | 6441 | 1.060 |
Why?
| Diabetic Angiopathies | 14 | 2018 | 222 | 1.040 |
Why?
| Vascular Stiffness | 6 | 2018 | 271 | 0.910 |
Why?
| Registries | 18 | 2021 | 1281 | 0.900 |
Why?
| Prevalence | 34 | 2021 | 1722 | 0.890 |
Why?
| Life Style | 13 | 2019 | 321 | 0.840 |
Why?
| Incidence | 30 | 2021 | 1791 | 0.830 |
Why?
| Triglycerides | 14 | 2019 | 397 | 0.810 |
Why?
| Polymorphism, Genetic | 17 | 2011 | 561 | 0.780 |
Why?
| Lipids | 10 | 2014 | 459 | 0.740 |
Why?
| Activities of Daily Living | 5 | 2002 | 261 | 0.740 |
Why?
| Middle Aged | 104 | 2019 | 20385 | 0.720 |
Why?
| Aged | 78 | 2019 | 14374 | 0.710 |
Why?
| Environmental Pollutants | 4 | 2020 | 77 | 0.690 |
Why?
| Child | 61 | 2022 | 12453 | 0.660 |
Why?
| Glucose Tolerance Test | 19 | 2012 | 265 | 0.650 |
Why?
| Hypoglycemic Agents | 14 | 2014 | 714 | 0.620 |
Why?
| Insulin Resistance | 15 | 2015 | 785 | 0.610 |
Why?
| Blood Pressure | 9 | 2017 | 1234 | 0.600 |
Why?
| Metformin | 13 | 2017 | 214 | 0.600 |
Why?
| Insulin | 19 | 2014 | 1537 | 0.590 |
Why?
| Diabetes Complications | 7 | 2021 | 172 | 0.580 |
Why?
| Blood Glucose | 18 | 2022 | 1365 | 0.580 |
Why?
| Rural Population | 8 | 2006 | 318 | 0.580 |
Why?
| Cholesterol, LDL | 8 | 2019 | 216 | 0.570 |
Why?
| Adiposity | 6 | 2018 | 346 | 0.570 |
Why?
| United States | 38 | 2021 | 8885 | 0.570 |
Why?
| Birth Weight | 3 | 2003 | 295 | 0.550 |
Why?
| Diabetes, Gestational | 6 | 2011 | 194 | 0.540 |
Why?
| Age of Onset | 7 | 2020 | 378 | 0.540 |
Why?
| Body Mass Index | 25 | 2017 | 1434 | 0.530 |
Why?
| Electronic Health Records | 4 | 2021 | 486 | 0.510 |
Why?
| Child, Preschool | 35 | 2022 | 6811 | 0.510 |
Why?
| Glycated Hemoglobin A | 16 | 2022 | 597 | 0.510 |
Why?
| Infant | 28 | 2022 | 5727 | 0.500 |
Why?
| Weight Loss | 7 | 2012 | 500 | 0.500 |
Why?
| Carotid Arteries | 2 | 2013 | 125 | 0.500 |
Why?
| Femoral Artery | 1 | 2013 | 115 | 0.490 |
Why?
| Prediabetic State | 6 | 2017 | 153 | 0.490 |
Why?
| Risk Assessment | 10 | 2016 | 2143 | 0.480 |
Why?
| Multiple Trauma | 2 | 2005 | 68 | 0.460 |
Why?
| Rural Health | 4 | 2002 | 70 | 0.460 |
Why?
| Infant, Newborn | 21 | 2020 | 3619 | 0.450 |
Why?
| Cholesterol | 8 | 2013 | 264 | 0.450 |
Why?
| Pregnancy Complications, Cardiovascular | 2 | 2003 | 58 | 0.440 |
Why?
| Genetic Variation | 9 | 2014 | 732 | 0.440 |
Why?
| Hypertension | 6 | 2017 | 842 | 0.440 |
Why?
| Logistic Models | 16 | 2008 | 1463 | 0.440 |
Why?
| Odds Ratio | 17 | 2008 | 768 | 0.430 |
Why?
| Health Surveys | 4 | 2008 | 344 | 0.430 |
Why?
| Apolipoproteins E | 5 | 2019 | 87 | 0.420 |
Why?
| Breast Feeding | 4 | 2011 | 258 | 0.420 |
Why?
| Diabetic Neuropathies | 4 | 1997 | 60 | 0.420 |
Why?
| Sex Factors | 26 | 2016 | 1441 | 0.420 |
Why?
| Age Factors | 23 | 2016 | 2277 | 0.420 |
Why?
| Apolipoproteins C | 2 | 2019 | 10 | 0.410 |
Why?
| Aging | 6 | 2008 | 1238 | 0.410 |
Why?
| Coronary Disease | 8 | 2012 | 327 | 0.400 |
Why?
| Case-Control Studies | 20 | 2019 | 2288 | 0.400 |
Why?
| Obesity | 10 | 2017 | 1866 | 0.390 |
Why?
| Disabled Persons | 2 | 2002 | 101 | 0.380 |
Why?
| Fluorocarbons | 2 | 2020 | 53 | 0.370 |
Why?
| Cohort Studies | 19 | 2019 | 3676 | 0.370 |
Why?
| Dietary Fats | 6 | 2011 | 256 | 0.350 |
Why?
| Maternal Exposure | 3 | 2018 | 105 | 0.340 |
Why?
| Follow-Up Studies | 15 | 2017 | 3446 | 0.340 |
Why?
| Health Status Disparities | 1 | 2008 | 151 | 0.330 |
Why?
| Regression Analysis | 16 | 2009 | 813 | 0.330 |
Why?
| Diabetic Ketoacidosis | 3 | 2020 | 104 | 0.330 |
Why?
| Exercise | 10 | 2008 | 1173 | 0.320 |
Why?
| Glucose Intolerance | 3 | 2007 | 85 | 0.320 |
Why?
| Dietary Fiber | 3 | 2011 | 34 | 0.320 |
Why?
| Polymorphism, Single Nucleotide | 8 | 2019 | 1542 | 0.320 |
Why?
| Environmental Exposure | 2 | 2020 | 312 | 0.320 |
Why?
| C-Peptide | 6 | 1998 | 99 | 0.310 |
Why?
| Diabetic Retinopathy | 5 | 2012 | 101 | 0.300 |
Why?
| Erythropoietin | 1 | 2006 | 64 | 0.300 |
Why?
| Self-Injurious Behavior | 2 | 2017 | 77 | 0.300 |
Why?
| Aged, 80 and over | 12 | 2013 | 4819 | 0.300 |
Why?
| Retinopathy of Prematurity | 1 | 2006 | 58 | 0.300 |
Why?
| Apolipoproteins A | 4 | 2003 | 13 | 0.300 |
Why?
| Fasting | 8 | 2017 | 189 | 0.300 |
Why?
| Femoral Fractures | 1 | 2005 | 55 | 0.290 |
Why?
| Adiponectin | 3 | 2013 | 165 | 0.290 |
Why?
| Hyperinsulinism | 2 | 2013 | 85 | 0.280 |
Why?
| Genotype | 19 | 2019 | 1512 | 0.280 |
Why?
| Gene Frequency | 13 | 2014 | 406 | 0.270 |
Why?
| Lipoproteins | 4 | 2019 | 124 | 0.260 |
Why?
| Autism Spectrum Disorder | 2 | 2017 | 179 | 0.260 |
Why?
| Patient Compliance | 5 | 2014 | 438 | 0.260 |
Why?
| Autoantibodies | 5 | 2014 | 886 | 0.260 |
Why?
| Algorithms | 4 | 2021 | 1124 | 0.260 |
Why?
| Linkage Disequilibrium | 10 | 2015 | 227 | 0.250 |
Why?
| Ohio | 5 | 2015 | 96 | 0.250 |
Why?
| Educational Status | 3 | 2008 | 304 | 0.250 |
Why?
| Mental Status Schedule | 2 | 1999 | 27 | 0.250 |
Why?
| Cross-Sectional Studies | 18 | 2021 | 3117 | 0.250 |
Why?
| Energy Intake | 4 | 2017 | 328 | 0.240 |
Why?
| Embryonic and Fetal Development | 1 | 2002 | 74 | 0.240 |
Why?
| Sex Distribution | 5 | 2008 | 265 | 0.230 |
Why?
| Catheters, Indwelling | 1 | 2002 | 62 | 0.230 |
Why?
| Pregnancy | 12 | 2019 | 3839 | 0.230 |
Why?
| Population Surveillance | 5 | 2016 | 325 | 0.230 |
Why?
| Health Status Indicators | 1 | 2002 | 131 | 0.230 |
Why?
| Overweight | 3 | 2017 | 341 | 0.230 |
Why?
| Socioeconomic Factors | 9 | 2011 | 802 | 0.230 |
Why?
| Genetic Association Studies | 4 | 2019 | 307 | 0.230 |
Why?
| Lipoprotein(a) | 2 | 2000 | 40 | 0.230 |
Why?
| Diet | 8 | 2011 | 767 | 0.220 |
Why?
| Transcription Factor 7-Like 2 Protein | 2 | 2011 | 20 | 0.220 |
Why?
| Endocrine Disruptors | 2 | 2019 | 29 | 0.220 |
Why?
| Tungsten | 1 | 2021 | 20 | 0.220 |
Why?
| Mass Screening | 5 | 2020 | 778 | 0.220 |
Why?
| Retrospective Studies | 14 | 2019 | 8051 | 0.220 |
Why?
| Arteriosclerosis | 6 | 2002 | 85 | 0.220 |
Why?
| Leptin | 2 | 2014 | 158 | 0.220 |
Why?
| Uterine Cervical Neoplasms | 8 | 2001 | 150 | 0.220 |
Why?
| Haplotypes | 9 | 2019 | 380 | 0.220 |
Why?
| Glycoproteins | 2 | 1999 | 238 | 0.210 |
Why?
| Cognition Disorders | 2 | 2008 | 422 | 0.210 |
Why?
| Apolipoproteins B | 2 | 2014 | 42 | 0.210 |
Why?
| Lipoprotein Lipase | 3 | 2013 | 69 | 0.210 |
Why?
| Spinal Cord Injuries | 1 | 2002 | 115 | 0.210 |
Why?
| Confidence Intervals | 6 | 2008 | 253 | 0.210 |
Why?
| Health Status | 2 | 1996 | 557 | 0.210 |
Why?
| Urinary Bladder Neoplasms | 1 | 2002 | 142 | 0.200 |
Why?
| Mortality | 4 | 2010 | 262 | 0.200 |
Why?
| Child Development | 2 | 2014 | 342 | 0.200 |
Why?
| Alleles | 10 | 2014 | 624 | 0.200 |
Why?
| Cytosine | 1 | 2019 | 42 | 0.200 |
Why?
| Prospective Studies | 12 | 2021 | 4425 | 0.200 |
Why?
| Apolipoprotein C-I | 1 | 2019 | 4 | 0.200 |
Why?
| Apolipoprotein C-II | 1 | 2019 | 4 | 0.200 |
Why?
| Nutrition Disorders | 1 | 1999 | 19 | 0.200 |
Why?
| African Americans | 6 | 2014 | 797 | 0.190 |
Why?
| Genetic Predisposition to Disease | 9 | 2017 | 1756 | 0.190 |
Why?
| Alzheimer Disease | 2 | 1999 | 301 | 0.190 |
Why?
| Dietary Carbohydrates | 2 | 1997 | 113 | 0.190 |
Why?
| Abortion, Spontaneous | 1 | 1999 | 57 | 0.190 |
Why?
| Fetal Blood | 3 | 2020 | 204 | 0.180 |
Why?
| Risk Reduction Behavior | 3 | 2017 | 161 | 0.180 |
Why?
| Cross-Cultural Comparison | 1 | 1998 | 57 | 0.180 |
Why?
| Fertility | 1 | 2019 | 103 | 0.180 |
Why?
| Apolipoprotein A-I | 1 | 1997 | 19 | 0.180 |
Why?
| Predictive Value of Tests | 9 | 2020 | 1454 | 0.180 |
Why?
| Phthalic Acids | 1 | 2018 | 15 | 0.180 |
Why?
| Smoking | 9 | 2008 | 1174 | 0.180 |
Why?
| Islets of Langerhans | 4 | 2014 | 509 | 0.180 |
Why?
| Cognition | 2 | 2008 | 691 | 0.170 |
Why?
| Phenols | 1 | 2018 | 54 | 0.170 |
Why?
| Multiple Organ Failure | 1 | 1998 | 112 | 0.170 |
Why?
| Ankle Brachial Index | 2 | 2015 | 26 | 0.170 |
Why?
| Receptor, Melanocortin, Type 4 | 1 | 2017 | 7 | 0.170 |
Why?
| Hyperglycemia | 4 | 2014 | 245 | 0.170 |
Why?
| Alpha-Ketoglutarate-Dependent Dioxygenase FTO | 1 | 2017 | 20 | 0.170 |
Why?
| Prognosis | 8 | 2013 | 2491 | 0.170 |
Why?
| Risk | 9 | 2013 | 697 | 0.170 |
Why?
| Weight Reduction Programs | 1 | 2017 | 69 | 0.160 |
Why?
| Autonomic Nervous System | 2 | 2013 | 58 | 0.160 |
Why?
| Time Factors | 13 | 2013 | 5005 | 0.160 |
Why?
| Chromans | 2 | 2007 | 15 | 0.160 |
Why?
| Renal Insufficiency, Chronic | 1 | 2021 | 322 | 0.160 |
Why?
| Milk | 2 | 1996 | 104 | 0.160 |
Why?
| Body Constitution | 2 | 1993 | 46 | 0.160 |
Why?
| Peripheral Nervous System Diseases | 1 | 1997 | 104 | 0.160 |
Why?
| Health Knowledge, Attitudes, Practice | 2 | 2006 | 858 | 0.160 |
Why?
| Brain-Derived Neurotrophic Factor | 1 | 2017 | 93 | 0.160 |
Why?
| Sex Characteristics | 4 | 2010 | 471 | 0.160 |
Why?
| Pediatric Obesity | 2 | 2018 | 281 | 0.150 |
Why?
| Diet, Atherogenic | 1 | 1995 | 6 | 0.150 |
Why?
| Medical History Taking | 2 | 2000 | 99 | 0.150 |
Why?
| India | 3 | 2020 | 93 | 0.150 |
Why?
| Cholesterol Ester Transfer Proteins | 1 | 2015 | 13 | 0.150 |
Why?
| Glutamate Decarboxylase | 3 | 2014 | 135 | 0.150 |
Why?
| Age Distribution | 4 | 2006 | 265 | 0.150 |
Why?
| Waist Circumference | 5 | 2018 | 104 | 0.150 |
Why?
| Multivariate Analysis | 7 | 2009 | 1098 | 0.150 |
Why?
| Disease Progression | 7 | 2018 | 1803 | 0.150 |
Why?
| Biofeedback, Psychology | 1 | 1995 | 25 | 0.150 |
Why?
| Pulse Wave Analysis | 4 | 2018 | 120 | 0.150 |
Why?
| PPAR gamma | 2 | 2007 | 135 | 0.150 |
Why?
| DNA | 2 | 2000 | 962 | 0.150 |
Why?
| Weight Gain | 2 | 1995 | 361 | 0.140 |
Why?
| Scavenger Receptors, Class B | 1 | 2014 | 8 | 0.140 |
Why?
| Thiazolidinediones | 2 | 2007 | 127 | 0.140 |
Why?
| Sensitivity and Specificity | 6 | 2016 | 1394 | 0.140 |
Why?
| Visual Perception | 1 | 1995 | 102 | 0.140 |
Why?
| Gestational Age | 3 | 2011 | 550 | 0.140 |
Why?
| Carbonated Beverages | 2 | 2011 | 18 | 0.140 |
Why?
| Receptor-Like Protein Tyrosine Phosphatases, Class 8 | 1 | 2014 | 38 | 0.140 |
Why?
| Menopause | 3 | 2011 | 194 | 0.140 |
Why?
| HLA-D Antigens | 1 | 1994 | 20 | 0.140 |
Why?
| HLA-A Antigens | 1 | 1994 | 40 | 0.140 |
Why?
| Proportional Hazards Models | 5 | 2012 | 828 | 0.140 |
Why?
| Prenatal Nutritional Physiological Phenomena | 1 | 2014 | 50 | 0.140 |
Why?
| HLA-B Antigens | 1 | 1994 | 40 | 0.140 |
Why?
| Lipoproteins, HDL | 2 | 1999 | 67 | 0.130 |
Why?
| Diabetic Cardiomyopathies | 1 | 2014 | 23 | 0.130 |
Why?
| Infant Food | 2 | 1996 | 54 | 0.130 |
Why?
| Heart Rate | 3 | 2013 | 584 | 0.130 |
Why?
| Indians, North American | 6 | 2020 | 436 | 0.130 |
Why?
| Depression | 1 | 2000 | 825 | 0.130 |
Why?
| HLA Antigens | 3 | 2008 | 176 | 0.130 |
Why?
| Postural Balance | 1 | 1995 | 145 | 0.130 |
Why?
| International Classification of Diseases | 2 | 2021 | 83 | 0.130 |
Why?
| Adolescent Development | 1 | 2013 | 81 | 0.130 |
Why?
| Nitrates | 1 | 1992 | 68 | 0.120 |
Why?
| Water Supply | 1 | 1992 | 46 | 0.120 |
Why?
| Hypercholesterolemia | 1 | 1992 | 63 | 0.120 |
Why?
| Dyslipidemias | 2 | 2019 | 113 | 0.120 |
Why?
| Poverty | 2 | 2006 | 342 | 0.120 |
Why?
| Physicians | 1 | 1998 | 511 | 0.120 |
Why?
| Health Promotion | 2 | 2014 | 454 | 0.110 |
Why?
| Demography | 6 | 2020 | 218 | 0.110 |
Why?
| Models, Statistical | 4 | 2013 | 477 | 0.110 |
Why?
| Brachial Artery | 2 | 2013 | 135 | 0.110 |
Why?
| Proinsulin | 1 | 2011 | 36 | 0.110 |
Why?
| Quality of Life | 2 | 2011 | 1511 | 0.110 |
Why?
| Treatment Outcome | 8 | 2017 | 6403 | 0.110 |
Why?
| Down-Regulation | 1 | 2013 | 477 | 0.110 |
Why?
| Myocardial Infarction | 2 | 1994 | 824 | 0.110 |
Why?
| Diet, Diabetic | 1 | 2011 | 26 | 0.110 |
Why?
| Cystic Fibrosis | 1 | 1998 | 603 | 0.110 |
Why?
| Family | 2 | 1993 | 429 | 0.110 |
Why?
| Sweetening Agents | 1 | 2011 | 35 | 0.110 |
Why?
| Dietary Sucrose | 1 | 2011 | 46 | 0.110 |
Why?
| Physical Exertion | 1 | 1991 | 180 | 0.100 |
Why?
| Outpatients | 1 | 1992 | 159 | 0.100 |
Why?
| Glucose-6-Phosphatase | 1 | 2009 | 21 | 0.100 |
Why?
| Phenotype | 6 | 2014 | 2163 | 0.100 |
Why?
| Analysis of Variance | 8 | 2011 | 1089 | 0.100 |
Why?
| Eating | 2 | 2004 | 231 | 0.100 |
Why?
| Adolescent Behavior | 1 | 2014 | 375 | 0.100 |
Why?
| Body Composition | 2 | 2004 | 531 | 0.100 |
Why?
| Fetal Growth Retardation | 1 | 2013 | 305 | 0.100 |
Why?
| Reproducibility of Results | 5 | 2013 | 2058 | 0.100 |
Why?
| Urban Health | 1 | 1989 | 70 | 0.100 |
Why?
| Carrier Proteins | 2 | 2004 | 586 | 0.100 |
Why?
| Isosorbide Dinitrate | 1 | 2009 | 3 | 0.100 |
Why?
| Hydralazine | 1 | 2009 | 7 | 0.100 |
Why?
| Inflammation | 1 | 2018 | 1666 | 0.100 |
Why?
| Intermittent Claudication | 1 | 1990 | 74 | 0.100 |
Why?
| Linear Models | 3 | 2013 | 632 | 0.100 |
Why?
| Bacteriuria | 1 | 1988 | 6 | 0.100 |
Why?
| Calcinosis | 1 | 2011 | 203 | 0.090 |
Why?
| Maternal Age | 2 | 2006 | 95 | 0.090 |
Why?
| HLA-DQ Antigens | 4 | 2008 | 139 | 0.090 |
Why?
| HLA-DR Antigens | 4 | 2008 | 173 | 0.090 |
Why?
| Nasal Mucosa | 1 | 1989 | 75 | 0.090 |
Why?
| Comorbidity | 4 | 2017 | 1141 | 0.090 |
Why?
| Ankle | 1 | 2008 | 50 | 0.090 |
Why?
| Biomarkers | 5 | 2020 | 2583 | 0.090 |
Why?
| Glucose Clamp Technique | 3 | 2010 | 142 | 0.090 |
Why?
| Sequence Analysis, DNA | 3 | 2015 | 560 | 0.090 |
Why?
| Carcinoma in Situ | 4 | 1991 | 29 | 0.090 |
Why?
| HLA-DQ beta-Chains | 3 | 2008 | 53 | 0.090 |
Why?
| Probability | 3 | 2006 | 209 | 0.090 |
Why?
| Adipose Tissue | 1 | 1991 | 466 | 0.090 |
Why?
| Smoking Prevention | 1 | 2008 | 119 | 0.090 |
Why?
| Minority Groups | 1 | 2008 | 137 | 0.090 |
Why?
| Polymerase Chain Reaction | 5 | 2008 | 789 | 0.090 |
Why?
| Receptors, Drug | 1 | 2007 | 15 | 0.090 |
Why?
| Vasodilator Agents | 1 | 2009 | 233 | 0.080 |
Why?
| Carcinoma, Squamous Cell | 4 | 2001 | 399 | 0.080 |
Why?
| Potassium Channels, Inwardly Rectifying | 1 | 2007 | 21 | 0.080 |
Why?
| ATP-Binding Cassette Transporters | 1 | 2007 | 80 | 0.080 |
Why?
| Shoulder Injuries | 1 | 2006 | 42 | 0.080 |
Why?
| Body Weight | 2 | 2009 | 731 | 0.080 |
Why?
| Potassium Channels | 1 | 2007 | 95 | 0.080 |
Why?
| Chi-Square Distribution | 3 | 2003 | 399 | 0.080 |
Why?
| Staphylococcus aureus | 1 | 1989 | 267 | 0.080 |
Why?
| Amino Acid Substitution | 1 | 2007 | 217 | 0.080 |
Why?
| Exercise Therapy | 3 | 2017 | 244 | 0.080 |
Why?
| Infant, Very Low Birth Weight | 1 | 2006 | 44 | 0.080 |
Why?
| Nutritional Sciences | 1 | 2006 | 27 | 0.080 |
Why?
| Trypsin Inhibitor, Kazal Pancreatic | 1 | 2005 | 4 | 0.080 |
Why?
| Joint Instability | 1 | 2006 | 98 | 0.080 |
Why?
| Bias | 2 | 1999 | 138 | 0.080 |
Why?
| Small-Area Analysis | 1 | 2005 | 9 | 0.080 |
Why?
| Abbreviated Injury Scale | 1 | 2005 | 16 | 0.080 |
Why?
| Epidemiologic Methods | 4 | 1992 | 54 | 0.080 |
Why?
| Orthopedics | 1 | 2006 | 96 | 0.070 |
Why?
| Coronary Artery Disease | 1 | 2011 | 508 | 0.070 |
Why?
| Smoking Cessation | 1 | 2008 | 266 | 0.070 |
Why?
| Lysine | 1 | 2007 | 181 | 0.070 |
Why?
| Statistics, Nonparametric | 3 | 2016 | 324 | 0.070 |
Why?
| Reference Values | 4 | 2003 | 575 | 0.070 |
Why?
| Computer Simulation | 2 | 2006 | 678 | 0.070 |
Why?
| Cost of Illness | 1 | 2006 | 211 | 0.070 |
Why?
| Health Maintenance Organizations | 1 | 2004 | 64 | 0.070 |
Why?
| Molecular Sequence Annotation | 2 | 2014 | 69 | 0.070 |
Why?
| Birth Order | 2 | 1994 | 9 | 0.070 |
Why?
| Alcohol Drinking | 3 | 1997 | 544 | 0.070 |
Why?
| Educational Measurement | 1 | 2006 | 210 | 0.070 |
Why?
| Health Behavior | 1 | 2008 | 543 | 0.070 |
Why?
| New York | 1 | 2003 | 86 | 0.070 |
Why?
| Tumor Virus Infections | 3 | 2001 | 55 | 0.060 |
Why?
| Prenatal Exposure Delayed Effects | 3 | 2014 | 344 | 0.060 |
Why?
| Papillomaviridae | 3 | 2001 | 92 | 0.060 |
Why?
| Busulfan | 1 | 1982 | 18 | 0.060 |
Why?
| Hydroxyurea | 1 | 1982 | 20 | 0.060 |
Why?
| Recombinant Proteins | 1 | 2006 | 1029 | 0.060 |
Why?
| Social Class | 2 | 2002 | 167 | 0.060 |
Why?
| Skinfold Thickness | 2 | 1992 | 34 | 0.060 |
Why?
| Leukemia, Myeloid | 1 | 1982 | 42 | 0.060 |
Why?
| Chlamydia Infections | 2 | 2000 | 46 | 0.060 |
Why?
| beta 2-Glycoprotein I | 2 | 1999 | 5 | 0.060 |
Why?
| Europe | 2 | 2013 | 268 | 0.060 |
Why?
| Diet, Reducing | 2 | 2017 | 65 | 0.060 |
Why?
| Christianity | 1 | 1981 | 5 | 0.060 |
Why?
| Psychological Tests | 1 | 2002 | 110 | 0.060 |
Why?
| Rehabilitation Centers | 1 | 2002 | 27 | 0.060 |
Why?
| Injury Severity Score | 2 | 2006 | 384 | 0.060 |
Why?
| Cultural Characteristics | 1 | 2002 | 51 | 0.060 |
Why?
| Papillomavirus Infections | 3 | 2001 | 147 | 0.060 |
Why?
| Dietary Proteins | 3 | 1997 | 79 | 0.060 |
Why?
| Primary Prevention | 1 | 2003 | 158 | 0.060 |
Why?
| Promoter Regions, Genetic | 2 | 2003 | 907 | 0.060 |
Why?
| Seasons | 3 | 1994 | 297 | 0.060 |
Why?
| Cause of Death | 1 | 2002 | 247 | 0.060 |
Why?
| Length of Stay | 1 | 2005 | 736 | 0.060 |
Why?
| Disability Evaluation | 1 | 2002 | 212 | 0.060 |
Why?
| Energy Metabolism | 1 | 2006 | 626 | 0.060 |
Why?
| Psychometrics | 2 | 2006 | 465 | 0.060 |
Why?
| Nursing Homes | 1 | 2002 | 96 | 0.050 |
Why?
| Epidemiological Monitoring | 1 | 2021 | 37 | 0.050 |
Why?
| Homocysteine | 1 | 2001 | 95 | 0.050 |
Why?
| Observational Studies as Topic | 1 | 2021 | 53 | 0.050 |
Why?
| Patient Education as Topic | 3 | 2011 | 544 | 0.050 |
Why?
| Autoimmunity | 2 | 2014 | 541 | 0.050 |
Why?
| Folic Acid | 1 | 2001 | 113 | 0.050 |
Why?
| Neoplasm Proteins | 1 | 2003 | 279 | 0.050 |
Why?
| Diabetic Nephropathies | 2 | 1994 | 199 | 0.050 |
Why?
| Microsatellite Repeats | 1 | 2000 | 121 | 0.050 |
Why?
| Heart Failure | 2 | 2009 | 1342 | 0.050 |
Why?
| Genome-Wide Association Study | 2 | 2017 | 873 | 0.050 |
Why?
| Combined Modality Therapy | 2 | 2014 | 864 | 0.050 |
Why?
| Molecular Sequence Data | 3 | 2000 | 2277 | 0.050 |
Why?
| Antibodies, Anticardiolipin | 1 | 1999 | 6 | 0.050 |
Why?
| Semen Analysis | 1 | 2019 | 8 | 0.050 |
Why?
| Time-to-Pregnancy | 1 | 2019 | 4 | 0.050 |
Why?
| Marital Status | 1 | 1999 | 35 | 0.050 |
Why?
| Antibodies, Antiphospholipid | 1 | 1999 | 22 | 0.050 |
Why?
| Physicians, Family | 1 | 2000 | 167 | 0.050 |
Why?
| Semen | 1 | 2019 | 27 | 0.050 |
Why?
| Phosphatidylserines | 1 | 1999 | 72 | 0.050 |
Why?
| Genetic Linkage | 2 | 2005 | 260 | 0.050 |
Why?
| Taiwan | 1 | 1998 | 10 | 0.050 |
Why?
| Sick Role | 1 | 1998 | 15 | 0.050 |
Why?
| Social Support | 1 | 2002 | 399 | 0.050 |
Why?
| Hypoglycemia | 1 | 2002 | 280 | 0.050 |
Why?
| Platelet Count | 1 | 1998 | 58 | 0.050 |
Why?
| APACHE | 1 | 1998 | 45 | 0.050 |
Why?
| Multigene Family | 1 | 2019 | 157 | 0.050 |
Why?
| Social Adjustment | 1 | 1998 | 54 | 0.050 |
Why?
| Personality Inventory | 1 | 1998 | 99 | 0.050 |
Why?
| Receptors, LDL | 1 | 1998 | 24 | 0.050 |
Why?
| Apolipoproteins | 1 | 1998 | 37 | 0.050 |
Why?
| Immunoglobulin M | 1 | 1999 | 186 | 0.040 |
Why?
| China | 1 | 1998 | 168 | 0.040 |
Why?
| Family Characteristics | 1 | 2019 | 114 | 0.040 |
Why?
| Double-Blind Method | 3 | 2009 | 1191 | 0.040 |
Why?
| Benzhydryl Compounds | 1 | 2018 | 43 | 0.040 |
Why?
| Behavior | 1 | 1998 | 75 | 0.040 |
Why?
| DNA Methylation | 1 | 2020 | 316 | 0.040 |
Why?
| Hospitalization | 3 | 2009 | 1215 | 0.040 |
Why?
| Alkanesulfonic Acids | 1 | 2017 | 11 | 0.040 |
Why?
| Transcription, Genetic | 1 | 2003 | 1048 | 0.040 |
Why?
| Caprylates | 1 | 2017 | 13 | 0.040 |
Why?
| Fluid Therapy | 1 | 1998 | 109 | 0.040 |
Why?
| Dietary Fats, Unsaturated | 1 | 1997 | 17 | 0.040 |
Why?
| Blood Group Antigens | 1 | 1997 | 14 | 0.040 |
Why?
| Geriatric Assessment | 1 | 1998 | 116 | 0.040 |
Why?
| alpha 1-Antichymotrypsin | 1 | 1997 | 3 | 0.040 |
Why?
| Nutritional Status | 1 | 1999 | 211 | 0.040 |
Why?
| Task Performance and Analysis | 1 | 1998 | 144 | 0.040 |
Why?
| Lipid Metabolism | 1 | 2000 | 408 | 0.040 |
Why?
| Receptors, Immunologic | 1 | 1998 | 147 | 0.040 |
Why?
| Quantitative Trait, Heritable | 1 | 1997 | 101 | 0.040 |
Why?
| Pregnancy Outcome | 1 | 2019 | 255 | 0.040 |
Why?
| Protective Factors | 1 | 2017 | 68 | 0.040 |
Why?
| Metabolome | 1 | 2019 | 219 | 0.040 |
Why?
| Environment | 2 | 2002 | 279 | 0.040 |
Why?
| Blood Transfusion | 1 | 1998 | 209 | 0.040 |
Why?
| Decision Trees | 1 | 1996 | 65 | 0.040 |
Why?
| Acculturation | 1 | 1996 | 42 | 0.040 |
Why?
| Milk Proteins | 1 | 1996 | 36 | 0.040 |
Why?
| Clinical Coding | 1 | 2016 | 10 | 0.040 |
Why?
| Forced Expiratory Flow Rates | 1 | 1975 | 15 | 0.040 |
Why?
| Peak Expiratory Flow Rate | 1 | 1975 | 28 | 0.040 |
Why?
| DNA, Mitochondrial | 1 | 1997 | 139 | 0.040 |
Why?
| Bronchitis | 1 | 1975 | 32 | 0.040 |
Why?
| Genetic Loci | 1 | 2017 | 204 | 0.040 |
Why?
| Uterine Cervical Diseases | 1 | 1995 | 5 | 0.040 |
Why?
| Chromosome Mapping | 2 | 1997 | 436 | 0.040 |
Why?
| Adenocarcinoma | 1 | 2001 | 591 | 0.040 |
Why?
| Immunoglobulin G | 1 | 1999 | 551 | 0.040 |
Why?
| Kidney | 1 | 2021 | 823 | 0.040 |
Why?
| Blood Glucose Self-Monitoring | 1 | 1998 | 311 | 0.040 |
Why?
| Blood Proteins | 1 | 1997 | 213 | 0.040 |
Why?
| Cleft Lip | 1 | 1994 | 26 | 0.040 |
Why?
| Cleft Palate | 1 | 1994 | 32 | 0.040 |
Why?
| Needs Assessment | 1 | 2016 | 253 | 0.040 |
Why?
| Societies, Medical | 1 | 1998 | 578 | 0.040 |
Why?
| Adaptation, Psychological | 1 | 1998 | 412 | 0.030 |
Why?
| Codon | 3 | 2003 | 68 | 0.030 |
Why?
| HLA-DQ alpha-Chains | 1 | 1994 | 11 | 0.030 |
Why?
| CD8-Positive T-Lymphocytes | 1 | 1998 | 506 | 0.030 |
Why?
| Overnutrition | 1 | 2014 | 39 | 0.030 |
Why?
| Nutrition Policy | 1 | 2014 | 43 | 0.030 |
Why?
| Multiple Sclerosis | 2 | 1988 | 231 | 0.030 |
Why?
| Neoplasm Invasiveness | 3 | 2001 | 311 | 0.030 |
Why?
| Abdominal Fat | 1 | 2013 | 36 | 0.030 |
Why?
| Glucose | 1 | 2017 | 580 | 0.030 |
Why?
| Population Groups | 1 | 2013 | 45 | 0.030 |
Why?
| Autoimmune Diseases | 1 | 1996 | 310 | 0.030 |
Why?
| Deoxyribonucleases, Type II Site-Specific | 1 | 1993 | 17 | 0.030 |
Why?
| Lipoproteins, HDL3 | 1 | 1992 | 1 | 0.030 |
Why?
| Lipoproteins, HDL2 | 1 | 1992 | 3 | 0.030 |
Why?
| Polymorphism, Restriction Fragment Length | 3 | 2000 | 58 | 0.030 |
Why?
| Health Education | 1 | 1995 | 221 | 0.030 |
Why?
| Practice Patterns, Physicians' | 1 | 2000 | 862 | 0.030 |
Why?
| Chromosomes, Human | 1 | 1992 | 33 | 0.030 |
Why?
| Anthropometry | 1 | 1993 | 138 | 0.030 |
Why?
| Databases, Factual | 1 | 2017 | 820 | 0.030 |
Why?
| American Heart Association | 1 | 2014 | 202 | 0.030 |
Why?
| Diuretics | 1 | 1992 | 56 | 0.030 |
Why?
| Drug Administration Schedule | 2 | 2005 | 561 | 0.030 |
Why?
| Paper | 1 | 1992 | 10 | 0.030 |
Why?
| Disease Susceptibility | 1 | 1994 | 275 | 0.030 |
Why?
| Blood Specimen Collection | 1 | 1992 | 25 | 0.030 |
Why?
| Remission Induction | 1 | 2012 | 189 | 0.030 |
Why?
| Morbidity | 1 | 1992 | 185 | 0.030 |
Why?
| Estrogen Replacement Therapy | 1 | 1992 | 101 | 0.030 |
Why?
| Intrauterine Devices | 1 | 1991 | 22 | 0.030 |
Why?
| Pennsylvania | 2 | 2001 | 84 | 0.030 |
Why?
| Genes | 1 | 1992 | 190 | 0.030 |
Why?
| Pediatrics | 1 | 1998 | 729 | 0.030 |
Why?
| Genetic Testing | 2 | 2005 | 258 | 0.030 |
Why?
| Calcium, Dietary | 1 | 2011 | 41 | 0.030 |
Why?
| Cattle | 1 | 1993 | 697 | 0.030 |
Why?
| Adrenergic beta-Antagonists | 1 | 1992 | 261 | 0.030 |
Why?
| Cyclosporins | 1 | 1990 | 47 | 0.030 |
Why?
| Fruit | 1 | 2011 | 87 | 0.030 |
Why?
| Vegetables | 1 | 2011 | 87 | 0.030 |
Why?
| Women's Health | 1 | 2011 | 182 | 0.020 |
Why?
| Motor Activity | 1 | 2014 | 550 | 0.020 |
Why?
| Extremities | 1 | 1990 | 80 | 0.020 |
Why?
| Bicarbonates | 2 | 1985 | 25 | 0.020 |
Why?
| Reagent Strips | 1 | 1988 | 4 | 0.020 |
Why?
| South Carolina | 1 | 2008 | 20 | 0.020 |
Why?
| Body Height | 1 | 2009 | 147 | 0.020 |
Why?
| Genetic Carrier Screening | 1 | 2008 | 18 | 0.020 |
Why?
| Biological Evolution | 1 | 1992 | 312 | 0.020 |
Why?
| Drug Combinations | 1 | 2009 | 228 | 0.020 |
Why?
| HLA-DRB1 Chains | 1 | 2008 | 76 | 0.020 |
Why?
| Behavior, Addictive | 1 | 2008 | 56 | 0.020 |
Why?
| Sex | 1 | 1987 | 5 | 0.020 |
Why?
| Drug Prescriptions | 1 | 2009 | 177 | 0.020 |
Why?
| Sulfonylurea Receptors | 1 | 2007 | 8 | 0.020 |
Why?
| Parity | 1 | 1987 | 76 | 0.020 |
Why?
| Creatinine | 1 | 1988 | 330 | 0.020 |
Why?
| Rotator Cuff | 1 | 2006 | 32 | 0.020 |
Why?
| Histocompatibility Antigens Class II | 1 | 2008 | 263 | 0.020 |
Why?
| Rotator Cuff Injuries | 1 | 2006 | 37 | 0.020 |
Why?
| Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 2 | 1996 | 38 | 0.020 |
Why?
| Leisure Activities | 1 | 2006 | 21 | 0.020 |
Why?
| Psychiatric Status Rating Scales | 1 | 2008 | 387 | 0.020 |
Why?
| Global Health | 1 | 2008 | 250 | 0.020 |
Why?
| Staphylococcal Infections | 1 | 1989 | 219 | 0.020 |
Why?
| Epidemiology | 1 | 1986 | 17 | 0.020 |
Why?
| Atherosclerosis | 1 | 2008 | 212 | 0.020 |
Why?
| Insulin Antibodies | 2 | 1996 | 92 | 0.020 |
Why?
| Protein Tyrosine Phosphatases | 2 | 1996 | 102 | 0.020 |
Why?
| Patient Selection | 1 | 2009 | 479 | 0.020 |
Why?
| Shoulder Joint | 1 | 2006 | 105 | 0.020 |
Why?
| Ketones | 1 | 1985 | 37 | 0.020 |
Why?
| Community Participation | 1 | 1986 | 68 | 0.020 |
Why?
| Nutrition Surveys | 1 | 2006 | 152 | 0.020 |
Why?
| Mutation, Missense | 1 | 2007 | 236 | 0.020 |
Why?
| DNA Primers | 2 | 1996 | 416 | 0.020 |
Why?
| Range of Motion, Articular | 1 | 2006 | 257 | 0.020 |
Why?
| Quality-Adjusted Life Years | 1 | 2005 | 75 | 0.020 |
Why?
| Markov Chains | 1 | 2005 | 89 | 0.020 |
Why?
| Orthopedic Procedures | 1 | 2006 | 147 | 0.020 |
Why?
| Acidosis | 1 | 1985 | 66 | 0.020 |
Why?
| Pancreatitis | 1 | 2005 | 74 | 0.020 |
Why?
| Uncoupling Protein 3 | 1 | 2004 | 9 | 0.020 |
Why?
| Asthma | 1 | 1975 | 1452 | 0.020 |
Why?
| DNA Mutational Analysis | 1 | 2005 | 315 | 0.020 |
Why?
| Teaching | 1 | 2006 | 160 | 0.020 |
Why?
| Statistics as Topic | 2 | 2000 | 247 | 0.020 |
Why?
| Case Management | 1 | 2004 | 53 | 0.020 |
Why?
| Referral and Consultation | 1 | 1988 | 470 | 0.020 |
Why?
| Ion Channels | 1 | 2004 | 95 | 0.020 |
Why?
| Genetics, Population | 1 | 2004 | 170 | 0.020 |
Why?
| Self Efficacy | 1 | 2006 | 245 | 0.020 |
Why?
| Hyperlipidemias | 1 | 2004 | 102 | 0.020 |
Why?
| Mexico | 2 | 1996 | 126 | 0.020 |
Why?
| Minisatellite Repeats | 1 | 2003 | 35 | 0.020 |
Why?
| Schools | 1 | 2006 | 282 | 0.020 |
Why?
| Vaginal Smears | 2 | 1995 | 36 | 0.020 |
Why?
| Fatty Acid-Binding Proteins | 1 | 2003 | 45 | 0.020 |
Why?
| Cost-Benefit Analysis | 1 | 2005 | 349 | 0.020 |
Why?
| Papanicolaou Test | 2 | 1995 | 36 | 0.020 |
Why?
| Mitochondrial Proteins | 1 | 2004 | 173 | 0.020 |
Why?
| Indiana | 1 | 1981 | 22 | 0.010 |
Why?
| Vitamin B 6 | 1 | 2001 | 6 | 0.010 |
Why?
| Alabama | 1 | 2001 | 26 | 0.010 |
Why?
| Illinois | 1 | 2001 | 20 | 0.010 |
Why?
| New Mexico | 1 | 2001 | 46 | 0.010 |
Why?
| Florida | 1 | 2001 | 57 | 0.010 |
Why?
| Severity of Illness Index | 1 | 2008 | 1983 | 0.010 |
Why?
| Bacteriological Techniques | 1 | 2001 | 47 | 0.010 |
Why?
| Culture | 1 | 2002 | 109 | 0.010 |
Why?
| Veterans | 1 | 2009 | 673 | 0.010 |
Why?
| Texas | 1 | 2001 | 134 | 0.010 |
Why?
| Kringles | 1 | 2000 | 5 | 0.010 |
Why?
| Deoxyribonuclease HindIII | 1 | 2000 | 3 | 0.010 |
Why?
| Polymorphism, Single-Stranded Conformational | 1 | 2000 | 27 | 0.010 |
Why?
| Vitamin B 12 | 1 | 2001 | 86 | 0.010 |
Why?
| Medicare | 1 | 2004 | 449 | 0.010 |
Why?
| Base Sequence | 2 | 1996 | 1697 | 0.010 |
Why?
| Chronic Disease | 1 | 2005 | 1154 | 0.010 |
Why?
| Acute Disease | 1 | 2002 | 721 | 0.010 |
Why?
| Physician Assistants | 1 | 2000 | 54 | 0.010 |
Why?
| Vitamins | 2 | 1991 | 109 | 0.010 |
Why?
| Arizona | 2 | 1978 | 48 | 0.010 |
Why?
| Chromatography, High Pressure Liquid | 1 | 2001 | 396 | 0.010 |
Why?
| Nurse Practitioners | 1 | 2000 | 85 | 0.010 |
Why?
| Enzyme-Linked Immunosorbent Assay | 1 | 2001 | 645 | 0.010 |
Why?
| Blood Preservation | 1 | 1982 | 194 | 0.010 |
Why?
| Cardiolipins | 1 | 1999 | 52 | 0.010 |
Why?
| Transients and Migrants | 1 | 1979 | 18 | 0.010 |
Why?
| Metabolic Syndrome | 1 | 2002 | 303 | 0.010 |
Why?
| Low Density Lipoprotein Receptor-Related Protein-1 | 1 | 1998 | 11 | 0.010 |
Why?
| Neoplasm Staging | 1 | 2001 | 861 | 0.010 |
Why?
| Antibodies, Viral | 1 | 2001 | 411 | 0.010 |
Why?
| Lymphocyte Count | 1 | 1998 | 97 | 0.010 |
Why?
| Proteinuria | 1 | 1998 | 72 | 0.010 |
Why?
| CD4 Lymphocyte Count | 1 | 1998 | 211 | 0.010 |
Why?
| Erythrocytes | 1 | 2001 | 397 | 0.010 |
Why?
| Nigeria | 1 | 1997 | 7 | 0.010 |
Why?
| Guideline Adherence | 1 | 2000 | 382 | 0.010 |
Why?
| Thrombosis | 1 | 1999 | 179 | 0.010 |
Why?
| Virus Diseases | 1 | 1998 | 124 | 0.010 |
Why?
| Bacterial Infections | 1 | 1998 | 156 | 0.010 |
Why?
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 1998 | 243 | 0.010 |
Why?
| Animals | 2 | 1996 | 25325 | 0.010 |
Why?
| Pneumonia | 2 | 1983 | 405 | 0.010 |
Why?
| Data Interpretation, Statistical | 1 | 1998 | 250 | 0.010 |
Why?
| Africa | 1 | 1996 | 63 | 0.010 |
Why?
| Histocompatibility Testing | 1 | 1996 | 94 | 0.010 |
Why?
| Marriage | 1 | 1997 | 80 | 0.010 |
Why?
| Quality Control | 1 | 1996 | 135 | 0.010 |
Why?
| Receptors, Cell Surface | 1 | 1998 | 292 | 0.010 |
Why?
| England | 1 | 1975 | 43 | 0.010 |
Why?
| Trichomonas Infections | 1 | 1995 | 6 | 0.010 |
Why?
| Genetic Markers | 1 | 1997 | 301 | 0.010 |
Why?
| Condylomata Acuminata | 1 | 1995 | 8 | 0.010 |
Why?
| T-Lymphocyte Subsets | 1 | 1998 | 334 | 0.010 |
Why?
| Cholesterol, Dietary | 1 | 1975 | 22 | 0.010 |
Why?
| Models, Biological | 1 | 2002 | 1260 | 0.010 |
Why?
| Cervix Uteri | 1 | 1995 | 35 | 0.010 |
Why?
| Eczema | 1 | 1975 | 47 | 0.010 |
Why?
| Primary Health Care | 1 | 2004 | 1058 | 0.010 |
Why?
| Gonorrhea | 1 | 1995 | 33 | 0.010 |
Why?
| Sex Ratio | 1 | 1994 | 12 | 0.010 |
Why?
| Mental Disorders | 1 | 2002 | 679 | 0.010 |
Why?
| Residence Characteristics | 1 | 1975 | 200 | 0.010 |
Why?
| Survival Analysis | 1 | 1996 | 981 | 0.010 |
Why?
| DNA, Viral | 1 | 1995 | 316 | 0.010 |
Why?
| Intrauterine Devices, Copper | 1 | 1991 | 7 | 0.010 |
Why?
| Sexual Behavior | 1 | 1995 | 325 | 0.010 |
Why?
| Pilot Projects | 1 | 1995 | 1046 | 0.010 |
Why?
| Altitude | 1 | 1994 | 340 | 0.010 |
Why?
| Mutation | 1 | 2000 | 2524 | 0.010 |
Why?
| Contraceptives, Oral | 1 | 1990 | 26 | 0.010 |
Why?
| Sexual Partners | 1 | 1990 | 103 | 0.010 |
Why?
| Random Allocation | 1 | 1990 | 289 | 0.010 |
Why?
| Dose-Response Relationship, Drug | 1 | 1991 | 1588 | 0.010 |
Why?
| Genital Diseases, Female | 1 | 1987 | 22 | 0.010 |
Why?
| Hydrogen-Ion Concentration | 1 | 1985 | 378 | 0.000 |
Why?
| Inhalation | 1 | 1983 | 19 | 0.000 |
Why?
| Disseminated Intravascular Coagulation | 1 | 1983 | 28 | 0.000 |
Why?
| Intubation, Intratracheal | 1 | 1983 | 141 | 0.000 |
Why?
| Clinical Trials as Topic | 1 | 1986 | 721 | 0.000 |
Why?
| Hawaii | 1 | 1979 | 30 | 0.000 |
Why?
| Japan | 1 | 1979 | 67 | 0.000 |
Why?
| Minnesota | 1 | 1978 | 63 | 0.000 |
Why?
| Feeding Behavior | 1 | 1979 | 386 | 0.000 |
Why?
|
|
Hamman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|